Carcinogenesis, Vol. 22, No. 11, 1885-1890,
November 2001
© 2001 Oxford University Press
SHORT COMMUNICATION |
Predominant mutation of codon 41 of the ß-catenin proto-oncogene in rat colon tumors induced by 1,2-dimethylhydrazine using a complete carcinogenic protocol
Department of Surgery, University Hospital of Heidelberg, INF 110, 69120, Heidelberg and
1 Central Unit of Biostatistics, Deutsches Krebsforschungszentrum, Heidelberg, Germany
Constitutive activation of the wnt-signaling pathway plays an important role during both human and rat colon carcinogenesis and can be brought through mutations in either the adenomatous polyposis coli or the ß-catenin gene. Mutations found in the ß-catenin gene typically affect one out of four regulatory phosphorylation sites near the N-terminus of the ß-catenin protein. Whereas in human colon cancers, however, the majority of ß-catenin mutations directly alter threonine 41 or serine 45; the ß-catenin mutations found in chemically induced rat colon tumors seemed to cluster around codon 33 instead. Unlike previous studies, that have used relatively short-term (2–5 weeks) treatment with one of the alkylating agents 1,2,-dimethylhydrazine (DMH) or azoxymethane, we have investigated the mutational spectrum of the ß-catenin gene in a panel of rat colon tumors induced by long-term (20 weeks) DMH-treatment. We detected ß-catenin mutations in 12 of 33 (36%) tumors. Interestingly, only one of the ß-catenin mutations found affected the previously implicated codon 33 cluster region (Asp32Asn), whereas 11 of 12 (>90%) mutations represented identical C
T transitions within codon 41 resulting in the common replacement of threonine by isoleucine. We propose a model in which codon 41 mutations bear higher oncogenic potential but are induced by DMH less frequently than mutations in the codon 33 cluster region. Consequently, only after sustained carcinogenic treatment, as is achieved in the long-term DMH-protocol, codon 41 mutations will be induced frequently enough to be present in all developing malignant lesions and, then, because of their higher oncogenic potential, these are selected for.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Peruzzi, F. Mori, A. Conforti, D. Lazzaro, E. De Rinaldis, G. Ciliberto, N. La Monica, and L. Aurisicchio MMP11: A Novel Target Antigen for Cancer Immunotherapy Clin. Cancer Res., June 15, 2009; 15(12): 4104 - 4113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Rosenberg, C. Giardina, and T. Tanaka Mouse models for the study of colon carcinogenesis Carcinogenesis, February 1, 2009; 30(2): 183 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Uronis, H. H. Herfarth, T. C. Rubinas, A. C. Bissahoyo, K. Hanlon, and D. W. Threadgill Flat Colorectal Cancers Are Genetically Determined and Progress to Invasion without Going through a Polypoid Stage Cancer Res., December 15, 2007; 67(24): 11594 - 11600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Santiago, B. Pagan, A. A. Isidro, and C. B. Appleyard Prolonged Chronic Inflammation Progresses to Dysplasia in a Novel Rat Model of Colitis-Associated Colon Cancer Cancer Res., November 15, 2007; 67(22): 10766 - 10773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. H.F. Chan, D. Cook, and C. P. Stanners Increased colon tumor susceptibility in azoxymethane treated CEABAC transgenic mice Carcinogenesis, September 1, 2006; 27(9): 1909 - 1916. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Currier, S. E. Solomon, E. G. Demicco, D. L. F. Chang, M. Farago, H. Ying, I. Dominguez, G. E. Sonenshein, R. D. Cardiff, Z.-X. J. Xiao, et al. Oncogenic Signaling Pathways Activated in DMBA-Induced Mouse Mammary Tumors Toxicol Pathol, October 1, 2005; 33(6): 726 - 737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tanaka, R. Suzuki, H. Kohno, S. Sugie, M. Takahashi, and K. Wakabayashi Colonic adenocarcinomas rapidly induced by the combined treatment with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and dextran sodium sulfate in male ICR mice possess {beta}-catenin gene mutations and increases immunoreactivity for {beta}-catenin, cyclooxygenase-2 and inducible nitric oxide synthase Carcinogenesis, January 1, 2005; 26(1): 229 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Provost, Y. Yamamoto, I. Lizardi, J. Stern, T. G. D'Aquila, R. B. Gaynor, and D. L. Rimm Functional Correlates of Mutations in {beta}-Catenin Exon 3 Phosphorylation Sites J. Biol. Chem., August 22, 2003; 278(34): 31781 - 31789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hagen, E. Di Daniel, A. A. Culbert, and A. D. Reith Expression and Characterization of GSK-3 Mutants and Their Effect on beta -Catenin Phosphorylation in Intact Cells J. Biol. Chem., June 21, 2002; 277(26): 23330 - 23335. [Abstract] [Full Text] [PDF]
|
|